CN101389320B - 使用α-羟基羰基化合物作为还原剂 - Google Patents

使用α-羟基羰基化合物作为还原剂 Download PDF

Info

Publication number
CN101389320B
CN101389320B CN200680053566.4A CN200680053566A CN101389320B CN 101389320 B CN101389320 B CN 101389320B CN 200680053566 A CN200680053566 A CN 200680053566A CN 101389320 B CN101389320 B CN 101389320B
Authority
CN
China
Prior art keywords
compound
reducing agent
formula
reduction
tretazicar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200680053566.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101389320A (zh
Inventor
理查德·约翰·诺克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaodian Pharmaceutical Co ltd
Original Assignee
Morvus Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morvus Technology Ltd filed Critical Morvus Technology Ltd
Priority to CN201710224938.5A priority Critical patent/CN107080746B/zh
Priority to CN201410341330.7A priority patent/CN104188943B/zh
Priority to CN201310241391.1A priority patent/CN103315995B/zh
Publication of CN101389320A publication Critical patent/CN101389320A/zh
Application granted granted Critical
Publication of CN101389320B publication Critical patent/CN101389320B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/02—Treatment of flour or dough by adding materials thereto before or during baking by adding inorganic substances
    • A21D2/06—Reducing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B31/00—Reduction in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN200680053566.4A 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂 Active CN101389320B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201710224938.5A CN107080746B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201410341330.7A CN104188943B (zh) 2005-12-29 2006-12-29 使用α‑羟基羰基化合物作为还原剂
CN201310241391.1A CN103315995B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526552.5 2005-12-29
GB0526552A GB0526552D0 (en) 2005-12-29 2005-12-29 New use
PCT/GB2006/004947 WO2007074344A1 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201310241391.1A Division CN103315995B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201710224938.5A Division CN107080746B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201410341330.7A Division CN104188943B (zh) 2005-12-29 2006-12-29 使用α‑羟基羰基化合物作为还原剂

Publications (2)

Publication Number Publication Date
CN101389320A CN101389320A (zh) 2009-03-18
CN101389320B true CN101389320B (zh) 2016-02-03

Family

ID=35841324

Family Applications (4)

Application Number Title Priority Date Filing Date
CN200680053566.4A Active CN101389320B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201410341330.7A Active CN104188943B (zh) 2005-12-29 2006-12-29 使用α‑羟基羰基化合物作为还原剂
CN201710224938.5A Active CN107080746B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201310241391.1A Active CN103315995B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201410341330.7A Active CN104188943B (zh) 2005-12-29 2006-12-29 使用α‑羟基羰基化合物作为还原剂
CN201710224938.5A Active CN107080746B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂
CN201310241391.1A Active CN103315995B (zh) 2005-12-29 2006-12-29 使用α-羟基羰基化合物作为还原剂

Country Status (15)

Country Link
US (3) US9029569B2 (https=)
EP (2) EP1951213B1 (https=)
JP (2) JP5368803B2 (https=)
KR (1) KR20080091354A (https=)
CN (4) CN101389320B (https=)
AU (1) AU2006329678B2 (https=)
CA (2) CA2826746C (https=)
ES (2) ES2399288T3 (https=)
GB (1) GB0526552D0 (https=)
IL (1) IL192507A0 (https=)
MX (1) MX2008008616A (https=)
NO (1) NO20082852L (https=)
NZ (1) NZ569483A (https=)
RU (2) RU2445078C2 (https=)
WO (1) WO2007074344A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
AU2009304542A1 (en) * 2008-10-15 2010-04-22 Xingnong Wang Use of tetrose to inhibit cancer and to increase cell viability
US20110216880A1 (en) * 2010-03-05 2011-09-08 General Electric Company System and method for molecular breast imaging
WO2011163671A2 (en) * 2010-06-25 2011-12-29 Boston Polymer Llc Environmentally benign plasticizers based on derivatives of acetone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154747A (en) * 1977-07-07 1979-05-15 Basf Aktiengesellschaft Production of virtually pure 1-amino-8-nitro-4,5-dihydroxyanthraquinone

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208999A (en) 1964-09-09 1965-09-28 Nat Starch Chem Corp Preparation of non-inhibited starch amines
US3658788A (en) * 1969-06-06 1972-04-25 Salk Inst For Biological Studi Aminooxazolines and products thereof and processes for synthesizing same
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
JPS52145523A (en) 1976-05-28 1977-12-03 Kouki Yagishita Antiitumor agent
CA1089763A (en) 1978-10-30 1980-11-18 Willard J. Johnson Rodenticide comprising 6-aminonicotinamide and 6- aminonicotinohydroxamic acid
CS204501B1 (en) 1978-11-06 1981-04-30 Miroslav Dub Shaped trap for regulation of the numbers of exoantropous and hemisynantropous rodents classes
US4375394A (en) * 1982-03-11 1983-03-01 Eastman Kodak Company Electrolytic process for the preparation of ethylene glycol and glycerine
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8804068D0 (en) * 1988-02-22 1988-03-23 Roberts J R Improvements relating to control of neoplastic tissue growth
CH680180B5 (https=) 1988-07-29 1993-01-15 Ciba Geigy Ag
DE3833194A1 (de) 1988-09-30 1990-04-05 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
DE4103639A1 (de) * 1991-02-07 1992-08-13 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
CA2122036C (en) 1991-10-23 2002-09-17 Gillian Anlezark Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4425436A1 (de) * 1994-07-19 1996-01-25 Basf Ag Verfahren zur Herstellung von Acyloinen
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5632782A (en) 1994-09-01 1997-05-27 Clariant Finance (Bvi) Ltd. Exhaust dyeing process for sulphur dyes
US20040053208A1 (en) 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
ATE247984T1 (de) 1997-02-11 2003-09-15 Univ Manchester Bioreduktive konjugate zur gezielten wirkstoffzufuhr
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB2365338B (en) 1997-06-14 2002-04-03 Enzacta R & D Ltd Therapeutic systems
US6159706A (en) 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
CN1302287A (zh) 1998-05-22 2001-07-04 盐野义生物研究公司 生物还原性细胞毒试剂
EP1104408A2 (en) 1998-08-19 2001-06-06 The Victoria University Of Manchester Drug targeting
CA2388844A1 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
MXPA02008637A (es) 2000-03-02 2004-09-06 Ml Lab Plc Elemento de respuesta a factor de celulas t.
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
DE10049468A1 (de) * 2000-10-06 2002-04-11 Bayer Ag N-Alkoxyalkyl-substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
DE102004009434A1 (de) * 2004-02-24 2005-12-15 Boehringer Ingelheim International Gmbh Zerstäuber
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
MXPA06014026A (es) 2004-07-02 2007-02-08 Warner Lambert Co Composiciones y metodos para tratar infecciones patogenas.
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154747A (en) * 1977-07-07 1979-05-15 Basf Aktiengesellschaft Production of virtually pure 1-amino-8-nitro-4,5-dihydroxyanthraquinone

Also Published As

Publication number Publication date
IL192507A0 (en) 2009-08-03
US20150231113A1 (en) 2015-08-20
CA2635388A1 (en) 2007-07-05
CA2826746A1 (en) 2007-07-05
EP1951213B1 (en) 2012-11-14
JP2009522244A (ja) 2009-06-11
AU2006329678B2 (en) 2013-05-09
CN103315995A (zh) 2013-09-25
CN103315995B (zh) 2019-03-15
US20100104515A1 (en) 2010-04-29
MX2008008616A (es) 2008-11-27
NO20082852L (no) 2008-09-29
CA2826746C (en) 2016-08-16
US10398676B2 (en) 2019-09-03
RU2008131054A (ru) 2010-02-10
CN107080746A (zh) 2017-08-22
AU2006329678A1 (en) 2007-07-05
EP1951213A1 (en) 2008-08-06
US9907784B2 (en) 2018-03-06
HK1204269A1 (en) 2015-11-13
WO2007074344A8 (en) 2007-12-27
CN104188943A (zh) 2014-12-10
JP2013116904A (ja) 2013-06-13
KR20080091354A (ko) 2008-10-10
JP5368803B2 (ja) 2013-12-18
JP5699170B2 (ja) 2015-04-08
CA2635388C (en) 2016-08-16
RU2011146556A (ru) 2013-05-27
CN104188943B (zh) 2017-04-12
WO2007074344A1 (en) 2007-07-05
GB0526552D0 (en) 2006-02-08
ES2623857T3 (es) 2017-07-12
EP2258430A2 (en) 2010-12-08
CN101389320A (zh) 2009-03-18
RU2445078C2 (ru) 2012-03-20
NZ569483A (en) 2012-09-28
EP2258430A3 (en) 2011-06-08
ES2399288T3 (es) 2013-03-27
EP2258430B1 (en) 2017-03-22
US20180140575A1 (en) 2018-05-24
US9029569B2 (en) 2015-05-12
CN107080746B (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
US10398676B2 (en) Use of alpha-hydroxy carbonyl compounds as reducing agents
AU2004226338C1 (en) Compositions and methods for treating cancer
Siim et al. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317
CN109689060A (zh) 组合化学治疗
Papadopoulou et al. NLCQ-1 (NSC 709257) Exploiting Hypoxia with a Weak DNA-Intercalating Bioreductive Drug
Zhu et al. A self-immobilizing photosensitizer with long-term retention for hypoxia imaging and enhanced photodynamic therapy
Jiang et al. Integration of Self‐Luminescence and Oxygen Self‐Supply: A Potential Photodynamic Therapy Strategy for Deep Tumor Treatment
HK1204269B (en) Use of alpha-hydroxy carbonyl compounds as reducing agents
HK1151482A (en) 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine
AU2013203344A1 (en) Use of alpha-hydroxy carbonyl compounds as reducing agents
Harfenist et al. A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise
HK1151482B (en) 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine
Jori et al. Zinc (II)-Phthalocyanine as a Second-Generation Photosensitizing Agent in Tumour Phototherapy
Passmore Synthesis and evaluation of redox-activated prodrug delivery systems as biological markers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210623

Address after: British Welsh

Patentee after: Gaodian Pharmaceutical Co.,Ltd.

Address before: British Welsh

Patentee before: MORVUS TECHNOLOGY Ltd.

TR01 Transfer of patent right